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Abstract
Background: Hyperglycemia is commonly observed in extremely low gestational age newborns (ELGANs) and is associated
with both increased morbidity and mortality. The objective of this study was to examine the relationship between neonatal
hyperglycemia and adiponectin levels in ELGANs.
Methodology/Principal Findings: Ten preterm infants between 22+6/7 and 27+3/7 weeks’ gestation with neonatal
hyperglycemia (defined as pre-feeding blood glucose levels above 200mg/dl on two consecutive measurements with a
maximum parenteral glucose infusion of 4mg/kg*min
21) formed the case cohort of this study. To every single patient of this
case cohort a patient with normal fasting (=pre-feeding) blood glucose levels was matched in terms of gestational age and
gender. Adiponectin ELISAs were performed both at onset of hyperglycemia and at term-equivalent age. In the case
cohort 9/10 patients had to be treated with insulin for 1–26 days (range 0.01–0.4 IU/kg*h
21). Compared to matched-paired
controls, significant hypoadiponectinemia was observed at onset of hyperglycemia in these affected patients (6.9mg/ml
versus 15.1mg/ml, p=0.009). At term equivalent age, normoglycemia without any insulin treatment was found in both
groups. Moreover, adiponectin levels at that time were no longer significantly different (12.3mg/ml versus 20.0mg/ml;
p=0.051) possibly indicating a mechanistic relevance of this adipokine in regulating insulin sensitivity in ELGANs.
Conclusions/Significance: Decreased circulating adiponectin levels are correlated with hyperglycemia in ELGANs and may
contribute to the pathogenesis of impaired glucose homeostasis in these infants. These findings suggest that adiponectin
might be a potential future drug target for the potentially save treatment of hyperglycemia in pre-term infants.
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Introduction
In extremely low birth weight (ELBW) premature infants and
extremely low gestational age newborns (ELGANs), respectively,
hyperglycemia is a commonly observed symptom and is associated
with both increased morbidity and mortality [1,2]. While elevated
blood glucose levels in these infants may be triggered by high
parenteral glucose administration, treatment with corticosteroids
and episodes of septic infection, the underlying mechanisms
evoking hyperglycemia in ELGANs often remain unclear.
Currently, besides caloric restriction, the only established thera-
peutic approach is administration of insulin, which may entail
potentially dangerous hypoglycemic episodes [3]. Identifying
factors that trigger hyperglycemia in premature born babies might
therefore form the basis of improved future therapeutic approach-
es to these babies.
In adults, the adipocytokine adiponectin enhances insulin
sensitivity and plays a pivotal role in the development of type 2
diabetes [4]. Intriguingly, circulating adiponectin levels in preterm
infants are substantially decreased as compared to term infants [5]
and analyses at term-equivalent age have shown a sustained
decrease of serum adiponectin concentrations of preterm infants in
comparison to term-born babies [6]. Since both premature birth
and small size at birth is a risk factor for developing type 2 diabetes
in later life [7,8], adiponectin might be a factor potentially linking
prematurity and adult metabolic disease.
To approach the question if circulating adiponectin levels may
influence neonatal glucose homeostasis in preterm infants, we
performed a matched-paired analysis in 20 ELGANs and
compared adiponectin levels in infants who had hyperglycemia
in the first weeks of life with preterm infants with unimpaired
glucose homeostasis who were matched in terms of gestational age
and gender. Intriguingly, we found that ELGANs who experi-
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The objective of this study was to examine the relationship
between neonatal hyperglycemia and adiponectin levels in
ELGANs. Thereby, we sought to test the hypothesis that ELGANs
with impaired glucose homeostasis had significantly decreased
circulating adiponectin levels as compared to normoglycemic
matched-paired ELGANs.
Participants
The study comprised 20 infants born before 28 full weeks of
gestation (range 22 6/7 to 27 3/7 weeks’ gestation) enrolled at two
institutions in Cologne. Gestational age was estimated from the
last menstrual period and this was supported by fetal ultrasound
measurements. Patients were eligible for inclusion into the case
cohort of the study if fasting (= pre-feeding) blood glucose levels
were above 200mg/dl on two consecutive measurements with a
maximum parenteral glucose infusion of 4mg/kg*min
21 and
without any infusion of lipids. Patients were eligible for inclusion
into the control cohort if they had fasting blood glucose levels
,180mg/dl without any insulin medication and could form a
matched pair with a patient of the case cohort in terms of
gestational age (61 week) and gender. Exclusion criteria for both
cohorts were clinical signs of infection or elevated C-reactive
protein (.3mg/dl) or blood Interleukin-6 (.50ng/l) values or
systemic steroid therapy.
Ethics
The study was approved by the ethics’ committee of the
University of Cologne, Germany. Written informed consent was
obtained from parents or legal guardians of every participant. All
patients participated on a completely voluntary basis.
Description of Procedures or Investigations undertaken
In the case cohort, blood samples for adiponectin measurement
were obtained within 24 hours after onset of hyperglycemia. In the
control cohort, blood samples were obtained at an age
corresponding to the chronological age (61 week) on which
adiponectin measurements were performed in the corresponding
matched case patient. In both cohorts, a second adiponectin
sample was obtained at term-equivalent age (61 week) and serum
adiponectin concentrations were determined as indicated below.
For all patients $23 0/7 weeks’ gestation, birth weight was jugded
to be appropriate for gestational age (AGA) or small for gestational
age (SGA) according to the percentile values of the body weight of
newborn infants by Voigt and colleagues [9]. In the case cohort,
one patient was SGA with a birth weight matching the 9
th
percentile, while all other patients had birth weights . the 10
th
percentile.
Enzyme-Linked Immunosorbent Assays (ELISA)
Patients’ sera were separated by centrifugation immediately
after the blood samples were obtained and were kept at –20uC
until analysis. Total serum adiponectin levels were determined by
ELISA using the Human Adiponectin ELISA Kit from BioVendor
(Czech Republic) as duplicate measurements with 10ml of patient’s
serum according to the manufacturer’s protocol (analytical
sensitivity: 0.47 ng/ml; intra-assay variability: 3.9%; inter-assay
variability: 6.0%). Leptin levels were determined as duplicate
measurements using kits from IBL international (Germany;
analytical sensitivity: 1.0 ng/ml) according to the manufacturer’s
protocol.
Statistical Methods
Statistical analysis was done using IBM SPSS Statistics Version
19. Circulating adiponectin levels of matched pairs were compared
by Wilcoxon’s signed-rank test both as measured and after
adjustment by dividing patient’s adiponectin values to their
individual body weight.
Results
This study comprised a cohort of 20 ELGANs, of whom ten
presented with severe fasting (= pre-feeding) hyperglycemia
(.200mg/dl) in the first weeks of life (case cohort). Every single
patient of the case cohort was matched by the criteria gestational
age and gender to a single patient with unimpaired glucose
homeostasis (control cohort). A summarized comparison of both
cohorts is shown in table 1. In both cohorts an equal distribution of
male and female patients (n=5 each) and a comparable
distribution of co-morbidities was observed. Detailed clinical
covariates of all patients are summarized in Table S1.
In the case cohort, nine of ten patients had to be treated with
insulin for 1–26 days (range 0.01–0.4 IU/kg*h
21; Table S1).
Mean circulating adiponectin concentrations at the time of the first
measurement (onset of hyperglycemia) in this cohort were 6.9 mg/
ml (range 2.6 mg/ml –15.1 mg/ml). In comparison, patients of the
control cohort had mean adiponectin levels of 15.1 mg/ml (range
3.6 mg/ml –27.5 mg/ml, Table 1). As shown in figure 1, the
differences in serum adiponectin concentrations between both
cohorts was of high statistical significance (p=0.0091). Moreover,
this difference remained statistically significant after adjusting
adiponectin values to patients’ individual body weight (p=0.013).
In addition, it was noted that except for a single pair (pair #1), all
patients who experienced an episode of hyperglycemia had lower
serum adiponectin values than their matched control counterparts
(Figure 1, Table S1), even if twins formed a matched pair. In
contrast, serum leptin concentrations at the time of hyperglycemia
were universally low in both the case and the control cohort
patients (,0.005ng/ml; below the detectable limit of the ELISA;
data not shown).
As adiponectin levels of preterm infants have been shown to rise
with increasing postnatal age [5], adiponectin levels were also
measured at term-equivalent age. Although no patient in either
group required insulin treatment at term-equivalent age, mean
adiponectin concentrations in the case cohort were still lower than
in the control cohort (12.3 mg/ml (range 7.5 mg/ml –20.2 mg/ml)
versus 20.0 mg/ml (range 9.9 mg/ml –35.5 mg/ml)). Although this
result had a strong trend towards statistical significance (p=0.051,
Figure 1, Table 1), this observation was not significant after
adjusting for patient’s body weight (p=0.11).
Discussion
Recent studies have shown that both babies who are small for
gestational age and preterm infants have lower circulating
adiponectin levels than appropriate for gestational age and term-
born babies, respectively [5,10]. While hypoadiponectinemia has
been shown to be associated with type 2 diabetes in adults [4], it is
unclear if low circulating adiponectin levels in preterm infants
contribute to the often impaired glucose tolerance of these babies.
Furthermore, it is unclear if adiponectin is linked to the increased
risk of premature or SGA infants to develop type 2 diabetes in
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paired analysis of a rare cohort of extremely premature infants to
compare serum adiponectin levels in ELGANs with hyperglycemia
in the first weeks of life to ELGANs with unimpaired glucose
homeostasis.
The central finding of our study was that very premature infants
with severe hyperglycemia had significantly lower circulating
adiponectin levels although leptin levels were univserally low in
both cohorts. It is tempting to hypothesize this observation might
indicate a mechanistic relevance of adiponectin in regulating
insulin sensitivity in preterm neonates. However, we think that our
data do not yet allow to conclude that adiponectin is mechanis-
tically responsible for hyperglycemia in extreme premature infants.
In contrast, it appears just as plausible that hyperglycemia and low
plasma adiponectin levels represent immaturity of beta cells and
adipose tissue, respectively, rather than being causally associated.
Future controlled trials are therefore needed to assess the impact of
adiponectin plasma levels on the glucose homeostasis of very
premature infants. If it can be proven that adiponectin is involved
in the pathogenesis of neonatal hyperglycemia, it appears
reasonable to consider inducing adiponectin production, e.g. by
pharmacologic interventions, as a future treatment option for
hyperglycemia in without the risk of hypoglycemic events that
come along with the administration of insulin [3]. However,
experience with currently available substances that raise adipo-
nectin levels, such as thiazolidinediones, appear not to warrant the
use of these drugs in ELGANs. Alternatively, since adiponectin has
been shown to be absorbed from breast milk in a biologically
active form [11], our data might further support feeding breast-
milk to ELGANs to positively affect the metabolism of these
infants. In this context, it is remarkable, that a previous studies by
Martin and colleagues showed a positive correlation of breast milk
adiponectin concentrations with mothers’ body mass index (BMI)
despite the known inverse correlation of adiponectin serum levels
with BMI [12], possibly indicating additional protective effects of
breast milk on the metabolic situation of newborn infants.
Similar to a recent trial by Saito and colleagues [13], who
described that serum adiponectin levels of preterm infants
increased from the first day of life to term-equivalent age, we
also observed a rise in circulating adiponectin levels from the time
of the first measurement to term-equivalent age both in the case
and the control cohort (Table S1). However, we also noted a few
patients in the control cohort with lower or equal serum
adiponectin levels at term-equivalent age (n=2 and n=1,
respectively). In contrast to the study by Saito, adiponectin levels
in these patients were not determined on the first day of life but at
24 and 25 days of life, respectively. Possibly, adiponectin levels in
these patients had already increased from birth to the time of the
first measurement and had reached a steady state on a sufficiently
high level, in particular since no hyperglycemia was noted in these
Table 1. Patients’ demographic criteria.
date of first measurement term-equivalent age
Control Cohort Case Cohort Control Cohort Case Cohort
patients numbers 10 10
twins 5 5
Male 5 5
gestational age [weeks] Mean 24 24,1
Standard Deviation 1,2 1,8
Minimum 22 22
Maximum 26 27
age at measurement [d] Mean 17,4 17,1 102 105
Minimum 6 6 76 68
Maximum 47 47 123 128
weight at measurement [g] Mean 706,8 642,4 2318,5 2170
Standard Deviation 165,6 110,4 237,4 430,2
Minimum 580 438 1970 1390
Maximum 1160 820 2730 2690
serum adiponectin levels Mean 15,1 6,9 20 12,3
Standard Deviation 9,7 4,7 10,2 4,6
Minimum 3,6 2,6 9,9 7,5
Median 12,3 4,9 18,6 10,8
Maximum 27,5 15,1 35,3 20,2
co-morbidity IVH uI-II 5 2
IVH uIII-IV 2 1
BPD 4 3
NEC uIII or higher 1 0
ROP.= uIII 0 2
PVL 0 1
Comparison of clinical and demographic parameters of patients and serum adiponectin levels of the control and the case cohort of the study.
doi:10.1371/journal.pone.0038481.t001
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observe an absolute adiponectin cutoff-level below which hyper-
glycemia universally occured. This phenomenon is most likely
attributed to the age-dependent rise in circulating adiponectin
concentrations, due to which adiponectin cut-off values may differ
depending on patients’ age. This hypothesis is supported by the
Figure 1. Serum adiponectin levels of ELGANs with and without hyperglycemia. Figure 1 indicates serum adiponectin levels both at the
time of the first analysis (onset of hyperglycemia (A) and at term-equivalent age (B). Serum adiponectin concentrations of patients with
hyperglycemia (case cohort) are shown on the right, those of patients with unimpaired glucose homeostasis are indicated on the left. Matched-pairs
of patients are indicated by identical symbols and are connected by a solid line. In figure 1B, no second adiponectin value is indicated for the case
patient of pair #9, as no second adiponectin sample was obtained for this patient.
doi:10.1371/journal.pone.0038481.g001
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cohort were observed in those patients who were the youngest at
the time of the analysis.
Limitations
An important limitation to our study is the low absolute number
of patients. Although we observed that circulating adiponectin
levels in ELGANs with hyperglycemia were significantly lower
than in infants who were normoglycemic, the low number of
patients in our study impedes a clear interpretation of the
differences in adiponectin levels between the two cohorts at term-
equivalent age. While it is intriguing that adiponectin levels of
patients with hyperglycemia tended to remain lower at term-
equivalent age than in control patients, this finding only had a
trend towards statistic significance (p=0.051). Therefore, analyses
of adiponectin levels in larger cohorts of patients are needed to
determine if hypoadiponectinemia persists at term-equivalent age
in patients who suffered from hyperglycemia in the first weeks of
life. It will be interesting to observe if this trend can be confirmed
and whether low adiponectin levels in patients who experienced
hyperglycemia in early life persist through future life. However it
also needs to be stressed that the patient cohort in this study is
extremely rare and that recruitment of these 20 patients had to be
performed over a 24-month period in two large neonatal intensive
care units in Germany. In view of this difficulty it also appears
reasonable that the pre-feeding blood glucose cutoff value was set
to ,180mg/dl for the control group and not to an even stricter
value, such as 150mg/dl. The finding of significantly different
serum adiponectin values in both cohorts retrospectively justifies
the chosen cutoff for the control cohort.
Future studies should address the question if infants with
hypoadiponectinemia in the first weeks of life are at an increased
risk of developing metabolic disease, such as type 2 diabetes, in
later life. If so, determining neonatal adiponectin levels could serve
as a risk predictor for metabolic disease in later life and could
eventually legitimate early dietary or even pharmacologic treat-
ment with either adiponectin inducing agents or substances that
mimic adiponectin effects.
Supporting Information
Table S1 Serum adiponectin concentrations and clini-
cal co-variates of patients who participated in the
present study. In addition to anthropometric parameter,
adiponectin values, blood glucose levels, insulin requirements,
the center, in which the patient was treated (1= University of
Cologne Children’s Hospital; 2= Children’s Hospital of the City
of Cologne) and information on both the reason for prematurity
and co-morbidities are indicated (IVH = intraventricular
hemorrhage; PVL = periventricular leukomalacia; BPD =
bronchopulmonary dysplasia; ROP = retinopathy of prematurity;
NEC = necrotizing enterocolitis). A value of 29999 corresponds
to missing information on this parameter.
(XLS)
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